FDA extends comment period on 510(k) modification draft notice

The FDA has extended the comment period for a draft guidance for industry and FDA staff on 510(k) modifications including how to decide when to submit a 510(k) for a change to an existing device.

The original draft notice was published July 27 in the Federal Register. Comments will assist the FDA in the development of a final guidance for industry and FDA staff.

The comment period is now open until Nov. 28.

“The agency believes that this will allow adequate time for interested persons to submit comments without significantly delaying action by the agency,” the notice, dated Nov. 8, concluded.

Around the web

RBMA President Peter Moffatt discusses declining reimbursement rates, recruiting challenges and the role of artificial intelligence in transforming the industry.

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.